Therefore, the aim of this study is to measure the effectiveness of GLP-1 and GLP-1/gastric inhibitory polypeptide (GIP) medications when combined with a continuous, digitally delivered behavioral change model involving a multidisciplinary team in the treatment of MetS components and weight among individuals with obesity in the UAE population. The gene discussed is GLP1R; the disease is obesity disorder.